| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJHEART.2008.06.019 |
| P698 | PubMed publication ID | 18768351 |
| P50 | author | Rutger J van Bommel | Q50684117 |
| Martin Jan Schalij | Q89053249 | ||
| P2093 | author name string | Jeroen J Bax | |
| Douwe E Atsma | |||
| Arnoud van der Laarse | |||
| Ernst E van der Wall | |||
| Gabe B Bleeker | |||
| Maureen M Henneman | |||
| Brigit den Adel | |||
| Margreet Klok | |||
| Marleen H M Hessel | |||
| Soban Umar | |||
| P2860 | cites work | Biochemical assessment of myocardial fibrosis in hypertensive heart disease | Q34441559 |
| Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. | Q34441567 | ||
| Recommendations for chamber quantification | Q34491436 | ||
| Cardiac fibrosis as a cause of diastolic dysfunction | Q34651778 | ||
| Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis | Q35582488 | ||
| Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system | Q37087344 | ||
| Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms | Q38776803 | ||
| Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. | Q43468133 | ||
| Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices | Q43727871 | ||
| Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives | Q43967724 | ||
| Myocardial collagen turnover in hypertrophic cardiomyopathy | Q44571604 | ||
| Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor | Q44820276 | ||
| Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. | Q50721869 | ||
| Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy. | Q51062399 | ||
| Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. | Q51590015 | ||
| Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. | Q55041198 | ||
| Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure | Q57259661 | ||
| Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation | Q57298941 | ||
| A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to Cardiac Resynchronization Therapy | Q57395352 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 878-883 | |
| P577 | publication date | 2008-09-02 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy | |
| P478 | volume | 10 |
| Q37903747 | Biomarkers: optimizing treatment guidance in heart failure |
| Q42856736 | Cardiac resynchronization therapy; the importance of evaluating cardiac metabolism |
| Q39284945 | Collagen isoform shift during the early phase of reverse left ventricular remodelling after relief of pressure overload |
| Q24630052 | Devices in the management of advanced, chronic heart failure |
| Q83450403 | Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure |
| Q42592404 | Evidence of scar tissue: contra-indication to cardiac resynchronization therapy? |
| Q41544213 | Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review. |
| Q44914311 | Improvement in collagen metabolism after 12 weeks' cardiac resynchronization therapy in patients with ischaemic cardiomyopathy |
| Q89181683 | Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR |
| Q64115562 | Low fibrosis biomarker levels predict cardiac resynchronization therapy response |
| Q57298801 | Myocardial collagen turnover after surgical ventricular restoration in heart failure patients |
| Q33994834 | Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity |
| Q37981970 | Transcriptome, proteome, and metabolome in dyssynchronous heart failure and CRT. |
Search more.